Literature DB >> 22785201

HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.

Danielle M Pineda1, David W Rittenhouse, Christopher C Valley, Joseph A Cozzitorto, Richard A Burkhart, Benjamin Leiby, Jordan M Winter, Matthew C Weber, Eric R Londin, Isidore Rigoutsos, Charles J Yeo, Myriam Gorospe, Agnieska K Witkiewicz, Jonathan N Sachs, Jonathan R Brody.   

Abstract

Apoptosis is one of the core signaling pathways disrupted in pancreatic ductal adenocarcinoma (PDA). Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF)-receptor superfamily that is expressed in cancer cells. Binding of TNF-related apoptosis-inducing ligand (TRAIL) to DR5 is a potent trigger of the extrinsic apoptotic pathway, and numerous clinical trials are based on DR5-targeted therapies for cancer, including PDA. Human antigen R (HuR), an RNA-binding protein, regulates a select number of transcripts under stress conditions. Here we report that HuR translocates from the nucleus to the cytoplasm of PDA cells upon treatment with a DR5 agonist. High doses of DR5 agonist induce cleavage of both HuR and caspase 8. HuR binds to DR5 mRNA at the 5'-untranslated region (UTR) in PDA cells in response to different cancer-associated stressors and subsequently represses DR5 protein expression; silencing HuR augments DR5 protein production by enabling its translation and thus enhances apoptosis. In PDA specimens (n = 53), negative HuR cytoplasmic expression correlated with elevated DR5 expression (odds ratio 16.1, p < 0.0001). Together, these data demonstrate a feedback mechanism elicited by HuR-mediated repression of the key apoptotic membrane protein DR5.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785201      PMCID: PMC3414415          DOI: 10.4161/cbt.20952

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  32 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

Review 2.  HuR's role in gemcitabine efficacy: an exception or opportunity?

Authors:  Jonathan R Brody; Gregory E Gonye
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-11-30       Impact factor: 9.957

Review 3.  Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.

Authors:  Annie Yang; Nicholas S Wilson; Avi Ashkenazi
Journal:  Curr Opin Cell Biol       Date:  2010-08-31       Impact factor: 8.382

4.  Transportin 2 regulates apoptosis through the RNA-binding protein HuR.

Authors:  Christopher von Roretz; Angelo M Macri; Imed-Eddine Gallouzi
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

5.  HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

Authors:  Nathan G Richards; David W Rittenhouse; Boris Freydin; Joseph A Cozzitorto; Dane Grenda; Hallgeir Rui; Greg Gonye; Eugene P Kennedy; Charles J Yeo; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Ann Surg       Date:  2010-09       Impact factor: 12.969

6.  RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation.

Authors:  D Durie; S M Lewis; U Liwak; M Kisilewicz; M Gorospe; M Holcik
Journal:  Oncogene       Date:  2010-11-22       Impact factor: 9.867

7.  Targeting TRAIL towards the clinic.

Authors:  Devalingam Mahalingam; Corina N A M Oldenhuis; Eva Szegezdi; Francis J Giles; Elisabeth G E de Vries; Steven de Jong; Steffan T Nawrocki
Journal:  Curr Drug Targets       Date:  2011-12       Impact factor: 3.465

8.  A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Authors:  N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William H Matsui; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-07-26       Impact factor: 6.261

9.  Post-transcriptional regulation of MEK-1 by polyamines through the RNA-binding protein HuR modulating intestinal epithelial apoptosis.

Authors:  Peng-Yuan Wang; Jaladanki N Rao; Tongtong Zou; Lan Liu; Lan Xiao; Ting-Xi Yu; Douglas J Turner; Myriam Gorospe; Jian-Ying Wang
Journal:  Biochem J       Date:  2010-02-24       Impact factor: 3.857

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  26 in total

1.  HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Authors:  Carmella Romeo; Matthew C Weber; Mahsa Zarei; Danielle DeCicco; Saswati N Chand; Angie D Lobo; Jordan M Winter; Janet A Sawicki; Jonathan N Sachs; Nicole Meisner-Kober; Charles J Yeo; Rajanikanth Vadigepalli; Mark L Tykocinski; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2016-04-06       Impact factor: 5.852

2.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Authors:  Richard A Burkhart; Danielle M Pineda; Saswati N Chand; Carmella Romeo; Eric R Londin; Edward D Karoly; Joseph A Cozzitorto; Isidore Rigoutsos; Charles J Yeo; Jonathan R Brody; Jordan M Winter
Journal:  RNA Biol       Date:  2013-06-13       Impact factor: 4.652

3.  Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.

Authors:  Weidan Peng; Narumi Furuuchi; Ludmila Aslanukova; Yu-Hung Huang; Samantha Z Brown; Wei Jiang; Sankar Addya; Vikalp Vishwakarma; Erika Peters; Jonathan R Brody; Dan A Dixon; Janet A Sawicki
Journal:  Mol Cell Biol       Date:  2018-01-16       Impact factor: 4.272

4.  RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.

Authors:  Mahsa Zarei; Shruti Lal; Ali Vaziri-Gohar; Kevin O'Hayer; Venugopal Gunda; Pankaj K Singh; Jonathan R Brody; Jordan M Winter
Journal:  Mol Cancer Res       Date:  2018-09-28       Impact factor: 5.852

5.  dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

Authors:  Florencia McAllister; Danielle M Pineda; Masaya Jimbo; Shruti Lal; Richard A Burkhart; Jennifer Moughan; Kathryn A Winter; Kotb Abdelmohsen; Myriam Gorospe; Ana de Jesus Acosta; Rachana H Lankapalli; Jordan M Winter; Charles J Yeo; Agnieska K Witkiewicz; Christine A Iacobuzio-Donahue; Daniel Laheru; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.

Authors:  Shruti Lal; Edwin C Cheung; Mahsa Zarei; Ranjan Preet; Saswati N Chand; Nicole C Mambelli-Lisboa; Carmella Romeo; Matthew C Stout; Eric Londin; Austin Goetz; Cinthya Y Lowder; Avinoam Nevler; Charles J Yeo; Paul M Campbell; Jordan M Winter; Dan A Dixon; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

7.  Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Authors:  Saswati N Chand; Mahsa Zarei; Matthew J Schiewer; Akshay R Kamath; Carmella Romeo; Shruti Lal; Joseph A Cozzitorto; Avinoam Nevler; Laura Scolaro; Eric Londin; Wei Jiang; Nicole Meisner-Kober; Michael J Pishvaian; Karen E Knudsen; Charles J Yeo; John M Pascal; Jordan M Winter; Jonathan R Brody
Journal:  Cancer Res       Date:  2017-07-07       Impact factor: 12.701

8.  Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Authors:  Yasuyoshi Miyata; Kensuke Mitsunari; Asai Akihiro; Shin-Ichi Watanabe; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

9.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 10.  Complex HuR function in pancreatic cancer cells.

Authors:  Jonathan R Brody; Dan A Dixon
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-02-16       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.